Contributions of advanced proteomics technologies to cancer diagnosis

被引：36
作者：
Ciordia S. [1 ]
de los Ríos V. [1 ]
Albar J.-P. [1 ]
机构：
[1] Proteomics Facility, Centro Nacional de Biotecnología-CSIC, Universidad Autónoma de Madrid, 28049 Madrid, C/ Darwin
来源：
Clinical and Translational Oncology | 2006年 / 8卷 / 8期
关键词：
Biomarkers; Cancer; Profiling; Proteomics; SELDI-TOF;
D O I：
10.1007/s12094-006-0062-4
中图分类号：
学科分类号：
摘要：
The ability of Medicine to effectively treat and cure cancer is directly dependent on their capability to detect cancers at their earliest stages. The advent of proteomics has brought with it the hope of discovering novel biomarkers in the early phases of tumorigenesis that can be used to diagnose diseases, predict susceptibility, and monitor progression. This discipline incorporates technologies that can be applied to complex biosystems such as serum and tissue in order to characterize the content of, and changes in, the proteome induced by physiological changes, benign or pathologic. These tools include 2-DE, 2D-DIGE, ICAT, protein arrays, MudPIT and mass spectrometries including SELDI-TOF. The application of these tools has assisted to uncover molecular mechanisms associated with cancer at the global level and may lead to new diagnostic tests and improvements in therapeutics. In this review these approaches are evaluated in the context of their contribution to cancer biomarker discovery. Particular attention is paid to the promising contribution of the ProteinChip/SELDI-TOF platform as a revolutionary approach in proteomic patterns analysis that can be applied at the bedside for discovering protein profiles that distinguish disease and disease-free states with high sensitivity and specificity. Understanding the basic concepts and tools used will illustrate how best to apply these technologies for patient benefit for the early cancer detection and improved patient care. © FESEO 2006.
引用
收藏
页码：566 / 580
页数：14
相关论文
共 108 条
[1]  
Lopez J.A., Bernat A., Albar J.P., Protein Expression Profiling Analysis in Hematopoietic Sttem Cells: Phenotipic of Mesenchymal Sttem Cells, Biomedical Applications of Proteomic, pp. 155-170, (2004)
[2]  
Hanash S., Integrated global profiling of cancer, Nat Rev Cancer, 8, pp. 638-644, (2004)
[3]  
Kolch W., Mischak H., Chalmers M.J., Et al., Clinical proteomics: A question of technology, Rapid Commun. Mass Spectrom, 18, pp. 2365-2366, (2004)
[4]  
Kolch W., Mischak H., Pitt A.R., The molecular make-up of a tumour: Proteomics in cancer research, Clin. Sci. (Lond.), 108, pp. 569-585, (2005)
[5]  
Gygi S.P., Corthals G.L., Zhang Y., Et al., Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology, Proc Natl Acad Sci, 97, pp. 9390-9395, (2000)
[6]  
Wilkins M.R., Gasteiger E., Bairoch A., Et al., Protein identification and analysis tools in the ExPASy server, Methods Mol Biol, 112, pp. 551-552, (1999)
[7]  
Yates J.R., Mass spectrometry: From genomics to proteomics, Trends Genet, 16, pp. 5-8, (2000)
[8]  
Gatlin C.L., Eng J.K., Cross S.T., Et al., Automated identification of amino acid sequence variations in proteins by HPLC/microscpray tandem mass spectrometry, Anal Chem, 72, pp. 757-765, (2000)
[9]  
Alaiya A., Al-Mohanna M., Linder S., Clinical cancer proteomics: Promises and pitfalls, Proteome Res, 4, pp. 1215-1222, (2005)
[10]  
Anderson L., Seilhamer J., A comparison of selected mRNA and protein abundances in human liver, Electrophoresis, 18, pp. 533-537, (1997)
12345678910